Immunocore Holdings PLC PRAME Investor and Analyst Event AT ESMO 2022 Transcript
(audio already in progress) to discuss the Phase 1 data from Immunocore's PRAME program. Before I begin, before we begin, I'd like to read some forward-looking statements.
During today's presentation, we'll be making certain forward-looking statements, including about development activities, business strategy, and the timing and impact of future events. Actual results could differ materially from those projected by these statements, which are based on management's views as of today and subject to risks and uncertainties, including those noted on most recent Form 20-F and in the 6-K we filed with the SEC. You're cautioned not to place undue reliance on these statements Immunocore disclaims any obligation to update them. We will also discuss non-IFRS measures in today's presentation, which is reconciled to the comparable IFRS measure in today's slides.
I'm now pleased to introduce our CEO, Dr. Bahija Jallal.
Thank you, Clay, and good evening,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |